MedTrace Logo

Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

NCT02315443 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 532

Last updated 2023-05-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

Conditions

  • Acute Cerebral Ischemia

Interventions

DRUG

Nerinetide (NA-1)

DRUG

Placebo

Sponsors & Collaborators

  • Brain Canada

    collaborator OTHER

  • Djavad Mowafaghian Centre for Brain Health

    collaborator UNKNOWN

  • Canadian Stroke Network

    collaborator OTHER

  • University of Calgary

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • University of British Columbia

    collaborator OTHER

  • Genome British Columbia

    collaborator INDUSTRY

  • NoNO Inc.

    lead INDUSTRY

Principal Investigators

  • Jim Christenson, M.D. · University of British Columbia

  • Richard Swartz, M.D. · Sunnybrook Health Sciences Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-26
Primary Completion
2023-03-27
Completion
2023-03-27

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315443 on ClinicalTrials.gov